Immunovant (IMVT) Stock Price, News & Analysis

Company Overview

Immunovant Inc. is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.

The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG. Efgartigimod is being evaluated in late-stage clinical trials for generalized myasthenia gravis and other indications, and has demonstrated the potential to provide rapid and durable reductions in pathogenic IgG levels. In addition to efgartigimod, Immunovant is advancing a pipeline of next-generation FcRn-targeted monoclonal antibodies designed to address a range of antibody-mediated diseases.

Founded in 2017 as a spin-out of Roivant Sciences, Immunovant is headquartered in New York, with research and development activities spanning North America and Europe. The company’s clinical programs involve global trial sites across key regions, and its leadership team comprises experienced executives and scientists with deep expertise in immunology and biologics development. Immunovant continues to collaborate with academic institutions and strategic partners to advance its FcRn-focused platform toward regulatory approval and commercial readiness.

Key Stats

• Today's Range: $40.82 to $42.16
• 50-Day Range: $30.80 to $42.60
• 52-Week Range: $14.47 to $42.92
• Volume: 303,477 shs
• Average Volume: 1.54 million shs
• Market Capitalization: $8.60 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $44.00
• Consensus Rating: Moderate Buy

Immunovant Stock Analysis - MarketRank™

Immunovant scored higher than 34% of companies evaluated by MarketBeat, and ranked 754th out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Immunovant has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 6 buy ratings, 3 hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for Immunovant is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Immunovant has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Immunovant are expected to decrease in the coming year, from ($2.72) to ($2.74) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Immunovant is -14.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Immunovant is -14.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Immunovant has a P/B Ratio of 11.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.08% of the float of Immunovant has been sold short.

Short Interest Ratio / Days to Cover

Immunovant has a short interest ratio ("days to cover") of 18.52, which indicates bearish sentiment.

Change versus previous month

Short interest in Immunovant has recently decreased by 7.79%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Immunovant does not currently pay a dividend.

Dividend Growth

Immunovant does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 1.04

News Sentiment

Immunovant has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Immunovant this week, compared to 4 articles on an average week.

Search Interest

Only 10 people have searched for IMVT on MarketBeat in the last 30 days. This is a decrease of -58% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Immunovant to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 1.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Immunovant insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,350,166.00 in company stock.

Percentage Held by Insiders

1.90% of the stock of Immunovant is held by insiders.

Percentage Held by Institutions

47.08% of the stock of Immunovant is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 8/14/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:IMVT
• CIK: 1764013
• Web: www.immunovant.com
• Phone: 917-580-3099
• Fax: N/A
• Employees: 120
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Immunovant: $44.00
• High Price Target: $62.00
• Low Price Target: $28.00
• Potential Upside/Downside: +5.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.82)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$505.61 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -69.59%
• Return on Assets: -62.49%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.27
• Quick Ratio: 7.27

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.56 per share
• Price / Book: 11.68

Miscellaneous

• Outstanding Shares: 206,550,000
• Free Float: 202,628,000
• Market Cap: $8.59 billion
• Optionable: Optionable
• Beta: 0.77